Wednesday, July 8, 2026

Patent intelligence · US

US 12296025

AAV capsid variants and uses thereof

granted A61KA61K47/64A61K48/0041A61K48/0058
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 19
Applicant portfolio 31
Patent details — US 12296025
Jurisdiction
US
Status
granted
Grant date
May 13, 2025
Expiration
May 8, 2045
Claims
30
CPC classes
A61K, A61K47/64, A61K48/0041, A61K48/0058
View on Google Patents ↗

Quick answer

US 12296025 (AAV capsid variants and uses thereof) is held by VOYAGER THERAPEUTICS, INC.. Status: granted. Granted May 13, 2025. Expires May 8, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
30
CPC classes
A61K, A61K47/64, A61K48/0041, A61K48/0058, A61K48/0075, A61K9/0019

More from VOYAGER THERAPEUTICS, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12419969

    AAV capsid variants and uses thereof

    VOYAGER THERAPEUTICS, INC. · Expires Sep 18, 2045

    granted
  2. US 12319929

    Compositions and methods for the treatment of Parkinson's disease

    VOYAGER THERAPEUTICS, INC. · Expires May 29, 2045

    granted
  3. US 12305189

    Compositions and methods for delivery of AAV

    VOYAGER THERAPEUTICS, INC. · Expires May 15, 2045

    granted
  4. US 12291565

    Tau binding compounds

    VOYAGER THERAPEUTICS, INC. · Expires May 1, 2045

    granted
  5. US 12281321

    Frataxin expression constructs having engineered promoters and methods of use thereof

    VOYAGER THERAPEUTICS, INC. · Expires Apr 17, 2045

    granted
  6. US 12252703

    Closed-ended linear duplex DNA for non-viral gene transfer

    VOYAGER THERAPEUTICS, INC. · Expires Mar 13, 2045

    granted
  7. US 12146150

    Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery

    VOYAGER THERAPEUTICS, INC. · Expires Nov 14, 2044

    granted

Frequently asked questions

What is US patent 12296025?

US 12296025 (AAV capsid variants and uses thereof) is held by VOYAGER THERAPEUTICS, INC.. Status: granted. Granted May 13, 2025. Expires May 8, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12296025?

VOYAGER THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 31 pharmaceutical patents for this assignee.

When does US 12296025 expire?

Our index shows an expiration date of May 8, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.